The Medicare hospital outpatient rate for the Argus II retinal prosthesis system has been set at $152,500 by CMS, Second Sight Medical Products announced in a press release.Argus II is the only FDA- and CE mark-approved device for the treatment of reti…
Author: Healio ophthalmology
Thyroid eye disease therapy shows promise
CHICAGO — Teprotumumab, an IGF-1 receptor antagonist antibody, demonstrated improvement of double vision in patients with thyroid eye disease, according to a study presented here.If approved by the FDA, teprotumumab (Horizon Pharma) would be the first …
VIDEO: Kala readies to launch Inveltys for cataract surgery
CHICAGO — At the Ophthalmology Innovation Summit at AAO, Mark Iwicki, chairman and CEO of Kala Pharmaceuticals, discusses the company’s plans to launch Inveltys (loteprednol etabonate ophthalmic suspension 1%), a twice-daily topical steroid, for the tr…
VIDEO: Oxurion introduces new clinical portfolio at OIS
CHICAGO At the Ophthalmology Innovation Summit at AAO, Patrik De Haes, MD, CEO of Oxurion, introduces the company’s new clinical portfolio with three separate molecules in clinical trials for the treatment of diabetic macular edema.
Repeated intravitreal sirolimus treatments improve vitreous haze
CHICAGO — The results of the integrated SAKURA program showed every-other-month dosing with intravitreal sirolimus improved ocular inflammation and vitreous haze in patients with non-infectious uveitis, according to a speaker here.Researchers evaluated…
Repeated intravitreal sirolimus treatments improve vitreous haze
CHICAGO — The results of the integrated SAKURA program showed every-other-month dosing with intravitreal sirolimus improved ocular inflammation and vitreous haze in patients with non-infectious uveitis, according to a speaker here.Researchers evaluated…
VIDEO: Glaucoma space treatment options advancing
CHICAGO – At the American Academy of Ophthalmology meeting, Manjool Shah, MD, discusses improvements in surgical technology in the glaucoma space, particularly focusing on the Allergan Xen gel stent for patients with refractory disease.
Compact Imaging, Novartis collaborate to develop home retinal monitoring system
Compact Imaging has signed a collaboration agreement with Novartis Pharma to develop a home-based monitor to detect progression of age-related macular degeneration and diabetic retinopathy, according to a press release.Using Compact Imaging’s MRO (Mult…
VIDEO: Manual cataract surgery tools promising in underserved communities
CHICAGO — At the American Academy of Ophthalmology meeting, Alan Crandall, MD, of Moran Eye Center, Utah, discusses using new tools and techniques to address the burden of cataract surgery in underserved communities.
Clearside’s retinal vein occlusion therapy fails to meet phase 3 endpoint
Xipere, an investigational treatment for retinal vein occlusion, did not achieve its phase 3 clinical trial primary endpoint, Clearside Biomedical announced in a press release.The multicenter, multi-country, randomized, masked phase 3 SAPPHIRE trial co…
VIDEO: Heidelberg launches OCTA module at AAO
CHICAGO — At the Ophthalmology Innovation Summit at AAO, Kfir Azoulay, head of corporate strategy at Heidelberg Engineering, discusses the launch of the company’s OCT angiography module for the Spectralis as well as other innovations taking place.
VIDEO: Neurotech progresses in MacTel, glaucoma treatment pipeline
CHICAGO ― At the Ophthalmology Innovation Summit at AAO, Richard Small, CPA, CEO of Neurotech Pharmaceuticals, discusses the phase 3 progress of encapsulated cell therapy, or ECP, for the treatment of macular telangiectasia or MacTel, as well as their …
DMEK prior to cataract surgery shows better results than combined procedure
CHICAGO — Compared with Descemet’s membrane endothelial keratoplasty combined with cataract surgery, performing cataract surgery after Descemet’s membrane endothelial keratoplasty provides patients with better uncorrected distance visual acuity, no sig…
Ophthotech acquires Versant Ventures-backed Inception 4
Ophthotech Corp. has acquired Inception 4 Inc. and its small molecule inhibitors of HtrA1, which are under development for the treatment of a range of retinal diseases, the company announced in a press release.Ophthotech obtained $6.1 million in cash t…
VIDEO: Pearls on using the ForeSee home to detect wet-AMD
CHICAGO — David S. Chin Yee, MD, discusses best practices in using the ForeSee home device to monitor AMD patients’ transition from dry to wet forms of the disease at the American Academy of Ophthalmology meeting here.
$name
Full Story →
$name
Full Story →
$name
Full Story →
$name
Full Story →
VIDEO: Santen initiates phase three studies of omidenepag for glaucoma
CHICAGO — At the American Academy of Ophthalmology meeting here, Ellie Chabi, MD, the therapeutic area head for glaucoma and neuroprotection and the lead for artificial intelligence programs within global biomedical science at Santen, discusses the ini…